CD3 News and Research

RSS

Therapeutic potential of CD20 x CD3 bispecific antibodies

On Monday, March 25th, 2024, the U.S. FDA declined approval for Regeneron’s Odronextamab for two forms of lymphoma due to concerns over the progress of ongoing confirmatory trials.

From Sino Biological Inc. 5 Apr 2024

New insights into upper tract urothelial carcinoma evolution and treatment

Researchers at Weill Cornell Medicine have performed the most comprehensive analysis to date of cancer of the ureters or the urine-collection cavities in the kidney, known as upper tract urothelial carcinoma (UTUC).

18 Mar 2024

Innovative therapy targets and destroys leukemia stem cells

Scientists at City of Hope, one of the largest cancer research and treatment organizations in the United States, have devised an innovative approach to target and destroy hard-to-kill leukemia stem cells.

26 Feb 2024

Smoking, infection, and BMI found to significantly sway immune response, study shows

Study reveals how smoking, CMV latent infection, and BMI significantly influence cytokine release, impacting immune response variability and potentially affecting disease risk.

14 Feb 2024

Researchers develop enhanced immunotherapy for multiple myeloma treatment

Immunotherapy is already improving treatment options for many cancer types, but research groups keep exploring ways to boost the body's immune response against the tumor.

14 Feb 2024

Gut enzyme discovery sheds light on bilirubin balance in humans

Researchers study identified BilR, a gut microbiota-derived enzyme, crucial for converting bilirubin to urobilinogen, impacting bilirubin homeostasis in humans.

7 Jan 2024

Gut microbiota linked to social anxiety behaviors

Study reveals that gut microbiota from individuals with social anxiety disorder (SAD) can induce social fear behaviors in mice, suggesting a causal role of gut microbes in modulating behaviors relevant to SAD.

2 Jan 2024

How immune cells shape our earliest breaths

Study profiles the development of immune cells in human lungs during embryonic and fetal stages, revealing their influence on epithelial cell fate and lung development.

1 Jan 2024

Double punch for B-cell lymphomas: CAR T-cell innovation boosts efficacy, cuts toxicity

The Malaghan Institute of Medical Research in collaboration with Wellington Zhaotai Therapies Limited today announced results of its phase 1 dose escalation trial of a new third-generation anti-CD19 chimeric antigen receptor (CAR) T-cell therapy to be presented at the American Society of Hematology (ASH) Annual Meeting in San Diego on 11 December, 3pm.

11 Dec 2023

Repeated mRNA vaccines supercharge immune response against COVID-19, study finds

Study published in Nature Immunology reveals that repeated mRNA COVID-19 vaccinations enhance immune response, especially in previously infected individuals, leading to a diversified and increased number of immune cell clones and a stronger ability to combat various virus strains.

7 Dec 2023

Study finds diet-derived trans-vaccenic acid boosts anti-tumor immunity

Dietary components that impact anti-tumor immunity.

28 Nov 2023

Pigeon virus causes fatal neurological disease in young leukemia patient

A case report details a fatal neurologic disease in an immunocompromised toddler caused by pigeon avian paramyxovirus, underscoring the effectiveness of metagenomic testing in diagnosing complex infectious diseases.

19 Nov 2023

B-BiTE modality enhances anti-myeloma effects of clinically available antibodies

Multiple myeloma still appears to be an incurable hematological malignancy. One of the reasons is that myeloma cells can be heterogenous and acquire resistance after anti-myeloma treatment.

16 Nov 2023

Overcoming T-cell exhaustion: A new hope for CAR-T cell therapy

CAR-T cell therapy is a last hope for many patients with blood, bone marrow or lymph gland cancer when other treatments such as chemotherapy are unsuccessful.

6 Nov 2023

Proof-of-concept study holds promise for safer gene therapy techniques for treating immunodeficiencies

Researchers described an approach to edit the recombination-activating gene 2 (RAG2) locus for therapeutic applications.

1 Nov 2023

Gut defenders: How T-cell intraepithelial lymphocytes guard against colon cancer

In the latest research published in Science Immunology, experts delve into the gene expression patterns of distinct intraepithelial lymphocyte populations in various gastrointestinal tract regions. Key findings reveal the roles of T-cell IELs in detecting infections and ensuring the gut's barrier integrity, with a special emphasis on their function in combating colon cancer.

9 Oct 2023

Universal screening: A game-changer in early detection and management of type 1 diabetes

Dr. Emily K. Sims discusses the crucial role of universal type 1 diabetes (T1D) screening in early detection, especially in individuals without a family history, at the EASD Annual Meeting. This proactive approach, aligned with disease-modifying therapies, aims to prevent severe diabetic ketoacidosis episodes, marking a stride towards better management of T1D.

3 Oct 2023

Study evaluating intranasal anti-CD3 for treatment of Alzheimer’s disease published in the PNAS journal

Tiziana Life Sciences Ltd. (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies via novel routes of drug delivery, today announced acceptance of a publication, “Nasal Administration of anti-CD3 monoclonal antibody (mAb) ameliorates disease in a mouse model of Alzheimer’s disease”, in the preeminent journal, Proceedings of the National Academy of Sciences (PNAS), that supports foralumab’s mechanism as a potential treatment for Alzheimer’s disease (AD), a difficult-to-treat neuroinflammatory disease.

9 Sep 2023

A SARS-CoV-2 spike-targeting bispecific T-cell engager strategy for controlling SARS-CoV-2 infection

Researchers described a novel strategy for controlling severe acute respiratory syndrome coronavirus 2.

5 Jun 2023

Unlocking the potential of RNA lipid nanoparticles to revolutionize cancer treatment

This paper discusses the use of RNA lipid nanoparticles for cancer immunotherapy, which has shown promising results in clinical use. However, only a small percentage of patients respond to existing immunotherapies, and the paper explores opportunities for improvement.

18 Apr 2023